This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Omeros Appoints Thomas A. Mitro As Vice President, Sales And Marketing

SEATTLE, Nov. 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the appointment of Thomas A. Mitro as vice president, sales and marketing.

Mr. Mitro has over 30 years of experience in the pharmaceutical industry, spanning sales and marketing as well as business development.  Prior to joining Omeros, Mr. Mitro served from 2002 until 2012 as vice president, sales and marketing at ISTA Pharmaceuticals, Inc. where he oversaw the building of ISTA's commercial infrastructure and launch of five eye care products. When ISTA was acquired by Bausch & Lomb in June of 2012, ISTA was the third largest branded prescription eye care business in the United States.  Before ISTA, Mr. Mitro served for over 20 years in various positions with Allergan, Inc., including vice president, skin care; vice president, business development; and vice president, e-business.  Mr. Mitro received his B.S. from Miami University.

"I am excited to join Omeros' impressive management team and to help advance the Company's products to market, starting with OMS302 for lens replacement surgery," stated Mr. Mitro.  "With two successful Phase 3 clinical trials, Omeros has a variety of options to commercialize OMS302, including going alone, partnering and co-promoting.  I believe that OMS302 will be widely used by ophthalmologists with the potential to generate significant revenues, and I look forward to contributing to its commercial success."

"We are very pleased to have Tom join Omeros as we prepare to launch OMS302," said Gregory A. Demopulos, M.D., Omeros' chairman and chief executive officer. "We are building an efficient commercialization strategy that can be targeted and levered to maximize success. Tom's years of experience in eye care – building industry-leading ophthalmic franchises – will be valuable to us as we refine and execute our strategy to deliver on OMS302's market potential."

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs